

Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/I0AD2B1233D6EN.html>

Date: March 2022

Pages: 140

Price: US\$ 2,000.00 (Single User License)

ID: I0AD2B1233D6EN

Abstracts

Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action

(MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 35 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Ischemia Reperfusion Injury - Overview
- Ischemia Reperfusion Injury - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Ischemia Reperfusion Injury - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
- Abfero Pharmaceuticals Inc
- Amyndas Pharmaceuticals LLC
- Anagenics Ltd
- Apollo Therapeutics LLC
- Argenx SE
- Asta Pharmaceuticals Co Ltd
- Axolo Pharma Inc
- Balmes Transplantation SAS
- Beijing Northland Biotech Co Ltd
- Bolder Biotechnology Inc
- Celdara Medical LLC
- CFM Pharma Holding BV
- Corline Biomedical AB
- Curacle Co Ltd
- Cypralis Ltd
- Domainex Ltd
- EVAS Therapeutics LLC
- Faron Pharmaceuticals Oy
- Gero Discovery
- Gilead Sciences Inc
- Glucox Biotech AB
- Ischemix Inc

Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
LUCA Science Inc
Mallinckrodt Plc
Neuroene Therapeutics LLC
New Beta Innovation Ltd
New Horizons Pharma Inc
Nour Heart Therapeutics LLC
NuNerve Pty Ltd
Orion Corp
Oxitope Pharma BV
Pfizer Inc
Pharming Group NV
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Revive Therapeutics Ltd
Sairiyo Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Slate Bio Inc
Stealth BioTherapeutics Corp
TheraSource LLC
United Therapeutics Corp
Young Therapeutics LLC
Ischemia Reperfusion Injury - Drug Profiles
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANV-6L15 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-39 - Drug Profile
Product Description
Mechanism Of Action
APP-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events

ARGX-117 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AZ-67 - Drug Profile

Product Description

Mechanism Of Action

BBT-059 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

History of Events

BT-0213 - Drug Profile

Product Description

Mechanism Of Action

BT-0301 - Drug Profile

Product Description

Mechanism Of Action

BT-0402 - Drug Profile

Product Description

Mechanism Of Action

bucillamine - Drug Profile

Product Description

Mechanism Of Action

History of Events

CAB-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

History of Events

CC-4066 - Drug Profile

Product Description

Mechanism Of Action

cerium oxide - Drug Profile

Product Description

Mechanism Of Action

CMX-2043 - Drug Profile

Product Description

Mechanism Of Action

History of Events

conestat alfa - Drug Profile

Product Description

Mechanism Of Action

History of Events

CU-103 - Drug Profile

Product Description

Mechanism Of Action

cyclocreatine phosphate - Drug Profile

Product Description

Mechanism Of Action

History of Events

DH-404 - Drug Profile

Product Description

Mechanism Of Action

dimethyltryptamine - Drug Profile

Product Description

Mechanism Of Action

History of Events

DMX-5804 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs for Ischemia Reperfusion Injuries - Drug Profile

Product Description

Mechanism Of Action

FAX-051T - Drug Profile

Product Description

Mechanism Of Action

Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis - Drug Profile

Product Description

Mechanism Of Action

HUB-1023 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IL-233 - Drug Profile

Product Description

Mechanism Of Action

interferon beta-1a - Drug Profile

Product Description

Mechanism Of Action

History of Events

KN-93 - Drug Profile

Product Description

Mechanism Of Action

M-3mP6 - Drug Profile

Product Description

Mechanism Of Action

MG-53 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MitoDak - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit MMP-8 for Ischemia Reperfusion Injury and Shock -
Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury and Inflammation -
Drug Profile

Product Description

Mechanism Of Action

History of Events

MP-3964 - Drug Profile

Product Description

Mechanism Of Action

Oligonucleotide for Cardiovascular Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

ORM-10103 - Drug Profile

Product Description

Mechanism Of Action

Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

R-190 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Enzymes to Activate ALDH2 for Alcohol Poisoning, Ischemia Reperfusion Injury and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile

Product Description

Mechanism Of Action

Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile

Product Description

Mechanism Of Action

Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

regadenoson - Drug Profile

Product Description

Mechanism Of Action

History of Events

Remodulin - Drug Profile

Product Description

Mechanism Of Action

Renaparin - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBT-272 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Ischemia Reperfusion Injury and Neuroinflammation - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Metastatic Liver Cancer and Hepatic Ischemia Reperfusion Injury -
Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug
Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CRP for Ischemic Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug
Profile

Product Description

Mechanism Of Action

SP-420 - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides for Cardiovascular Disorders, Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

tiomolibdate diammonium - Drug Profile

Product Description

Mechanism Of Action

tofacitinib citrate - Drug Profile

Product Description

Mechanism Of Action

UWA-TAT - Drug Profile

Product Description

Mechanism Of Action

Vanadis-01 - Drug Profile

Product Description

Mechanism Of Action

Vanadis-03 - Drug Profile

Product Description

Mechanism Of Action

VCP-746 - Drug Profile

Product Description

Mechanism Of Action

YQ-23 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YT-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YT-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YT-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ZK-001 - Drug Profile

Product Description

Mechanism Of Action

Ischemia Reperfusion Injury - Dormant Projects

Ischemia Reperfusion Injury - Discontinued Products

Ischemia Reperfusion Injury - Product Development Milestones

Featured News & Press Releases

Feb 15, 2022: Revive Therapeutics receives FDA Orphan Drug Designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation

Jan 17, 2022: Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection, 0.4 mg/5 mL (0.08 mg/mL) single-dose pre-filled syringe

Nov 23, 2021: Revive Therapeutics files for FDA Orphan Drug Designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation

Jun 19, 2021: 'Recombinant Human Thymosin ?4 for Injection' Phase IIa Clinical Trial Interim Investigator Meeting Successfully Held

Jan 20, 2020: Revive Therapeutics provides update on its cannabinoid program initiatives for drug delivery and in the prevention of ischemia and reperfusion injury from organ transplantation

May 05, 2019: Clinical trial shows promise for increasing lung transplant patients life expectancy

Aug 22, 2018: Revive Therapeutics applies to FDA For Orphan Drug Designation of Cannabidiol for treatment of Liver Transplantation

Jun 12, 2018: Corline Biomedical: Application for clinical trial of Renaparin submitted

Mar 26, 2018: UVA Launches Human Tests of Lung Transplant Drug

Aug 03, 2017: Corline Biomedical: Notice of allowance for Renaparin patent in the United States

May 04, 2017: Corline receives orphan drug status in the United States

Jan 27, 2017: Notice on the Start of Phase II Clinical Trial using 5-ALA by University of Oxford and SBI Pharmaceuticals

Dec 09, 2015: Ischemix Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

Sep 30, 2015: Ischemix Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients

Jul 02, 2012: Pharming Announces Publication Of New Data On Ruconest's Protective Effects After Severe Blood Loss In Journal Shock

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Ischemia Reperfusion Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ischemia Reperfusion Injury - Pipeline by Abfero Pharmaceuticals Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Anagenics Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Apollo Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Argenx SE, 2022
Ischemia Reperfusion Injury - Pipeline by Asta Pharmaceuticals Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Axolo Pharma Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, 2022
Ischemia Reperfusion Injury - Pipeline by Beijing Northland Biotech Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, 2022
Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, 2022
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, 2022
Ischemia Reperfusion Injury - Pipeline by Curacle Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Cypralis Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Domainex Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by EVAS Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Faron Pharmaceuticals Oy, 2022
Ischemia Reperfusion Injury - Pipeline by Gero Discovery, 2022
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, 2022

Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Larix Bioscience LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by LUCA Science Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, 2022
Ischemia Reperfusion Injury - Pipeline by Neuroene Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by New Beta Innovation Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by New Horizons Pharma Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Nour Heart Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by NuNerve Pty Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Orion Corp, 2022
Ischemia Reperfusion Injury - Pipeline by Oxitope Pharma BV, 2022
Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, 2022
Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Revive Therapeutics Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Sairiyo Therapeutics Inc, 2022
Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Slate Bio Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, 2022
Ischemia Reperfusion Injury - Pipeline by TheraSource LLC, 2022
Ischemia Reperfusion Injury - Pipeline by United Therapeutics Corp, 2022
Ischemia Reperfusion Injury - Pipeline by Young Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Dormant Projects, 2022
Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..1)
Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..2)
Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..3)
Ischemia Reperfusion Injury - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ischemia Reperfusion Injury, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/I0AD2B1233D6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I0AD2B1233D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

